AAV5基因治疗后人体血浆中转基因产生的B结构域缺失型凝血因子VIII的活性
本研究分析valoctocogene roxaparvovec(AAV5-FVIII-SQ)基因治疗后转基因产生的B结构域缺失型凝血因子VIII(FVIII-SQ)在血浆中的活性。意外发现转基因组FVIII-SQ在一期凝固法(OS)中的活性为发色底物法(CS)的1.3至2.0倍,而重组FVIII-SQ产品则OS低于CS;两种来源FVIII-SQ在CS法中比活性相当。进一步实验显示转基因组FVIII-SQ加速早期因子Xa和凝血酶形成,整体凝血酶水平未受影响。
要点
- 转基因产生的FVIII-SQ在一期凝固法中的活性为发色底物法的1.3至2.0倍。
- 重组FVIII-SQ产品的一期凝固法活性低于发色底物法活性。
- 转基因组与重组FVIII-SQ在发色底物法中的比活性相当。
核心结论
- 转基因产生的FVIII-SQ在一期凝固法中的活性高于发色底物法,而重组FVIII-SQ产品则相反,差异源于一期凝固法。
- 转基因组FVIII-SQ加速早期因子Xa和凝血酶形成,可解释基于动力学偏倚的一期凝固法活性较高,但整体凝血酶水平未受影响。
- 一期凝固法和发色底物法测得的FVIII活性均与关节出血相关,在临床上仍可区分血友病与非血友病FVIII活性水平。
- 临床开发中选择发色底物法活性作为替代终点,以保守评估止血疗效并与重组FVIII-SQ产品比较。
研究设计与样本
- 基于AAV5基因治疗药物valoctocogene roxaparvovec(AAV5-FVIII-SQ)的研究,相关试验注册号为NCT02576795、NCT03370913、EudraCT 2014-003880-38和EudraCT 2017-003215-19。
- 进一步实验纳入2名参与者。
主要发现
- 转基因产生的FVIII-SQ在一期凝固法中的活性为发色底物法的1.3至2.0倍。
- 重组FVIII-SQ产品的一期凝固法活性低于发色底物法活性。
- 转基因组与重组FVIII-SQ在发色底物法中的比活性(国际单位/毫克)相当,表明活性差异出现在一期凝固法中。
- 在多种检测试剂盒和临床实验室中均观察到转基因组FVIII-SQ的一期凝固法活性较高,提示内在分子特征是潜在根本原因。
- 在2名参与者中的进一步实验显示,转基因产生的FVIII-SQ加速早期因子Xa和凝血酶形成,整体凝血酶水平未受影响。
临床怎么用
- 临床开发中选择发色底物法活性作为替代终点,以保守评估止血疗效并与重组FVIII-SQ产品比较。
局限性
- 进一步实验仅纳入2名参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adeno-associated virus (AAV)-based gene therapies can restore endogenous factor VIII (FVIII) expression in hemophilia A (HA). AAV vectors typically use a B-domain-deleted FVIII transgene, such as human FVIII-SQ in valoctocogene roxaparvovec (AAV5-FVIII-SQ). Surprisingly, the activity of transgene-produced FVIII-SQ was between 1.3 and 2.0 times higher in one-stage clot (OS) assays than in chromogenic-substrate (CS) assays, whereas recombinant FVIII-SQ products had lower OS than CS activity. Transgene-produced and recombinant FVIII-SQ showed comparable specific activity (international units per milligram) in the CS assay, demonstrating that the diverging activities arise in the OS assay. Higher OS activity for transgene-produced FVIII-SQ was observed across various assay kits and clinical laboratories, suggesting that intrinsic molecular features are potential root causes. Further experiments in 2 participants showed that transgene-produced FVIII-SQ accelerated early factor Xa and thrombin formation, which may explain the higher OS activity based on a kinetic bias between OS and CS assay readout times. Despite the faster onset of coagulation, global thrombin levels were unaffected. A correlation with joint bleeds suggested that both OS and CS assay remained clinically meaningful to distinguish hemophilic from nonhemophilic FVIII activity levels. During clinical development, the CS activity was chosen as a surrogate end point to conservatively assess hemostatic efficacy and enable comparison with recombinant FVIII-SQ products. Relevant trials are registered on clinicaltrials.gov as #NCT02576795 and #NCT03370913 and, respectively, on EudraCT (European Union Drug Regulating Authorities Clinical Trials Database; https://eudract.ema.europa.eu) as #2014-003880-38 and #2017-003215-19.
引用
- Rosen S, Tiefenbacher S, Robinson M, et al. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. Blood. 2020. PMID: 32915950. doi:10.1182/blood.2020005683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。